Amgen Surpasses Estimates, Raises Full-Year Guidance Amid Strong Commercial Performance

Amgen Inc. (AMGN) reported a strong second quarter performance, exceeding revenue and EPS estimates.

The company's commercial portfolio, driven by Repatha, Uplizna, Evenity, Tezspire, and Imdeltra, continues to outperform expectations despite $7 billion in LOE headwinds.

Amgen raised its full-year revenue guidance by $1 billion and EPS guidance by $0.50, respectively.

The company's net debt of $43.3 billion limits major M&A activities, but in-licensing and bolt-on deals remain viable options.